|
|
Volumn 6, Issue 6, 2010, Pages 951-965
|
|
Dose-dense chemotherapy for breast cancer: what does the future hold?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
GRANULOCYTE COLONY STIMULATING FACTOR;
ADJUVANT CHEMOTHERAPY;
ADJUVANT THERAPY;
ADULT;
AGE;
AGED;
BREAST TUMOR;
CHEMICALLY INDUCED DISORDER;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG ADMINISTRATION;
DRUG DELIVERY SYSTEM;
FEMALE;
FORECASTING;
HUMAN;
MIDDLE AGED;
MULTICENTER STUDY;
MULTIMODALITY CANCER THERAPY;
NEUTROPENIA;
PERSONALIZED MEDICINE;
PHASE 3 CLINICAL TRIAL;
REVIEW;
STATISTICS;
ADULT;
AGE FACTORS;
AGED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
CLINICAL TRIALS AS TOPIC;
CLINICAL TRIALS, PHASE III AS TOPIC;
COMBINED MODALITY THERAPY;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
DRUG DELIVERY SYSTEMS;
FEMALE;
FORECASTING;
GRANULOCYTE COLONY-STIMULATING FACTOR;
HUMANS;
INDIVIDUALIZED MEDICINE;
MIDDLE AGED;
MULTICENTER STUDIES AS TOPIC;
NEOADJUVANT THERAPY;
NEUTROPENIA;
MLCS;
MLOWN;
|
|
EID: 77957258083
PISSN: None
EISSN: 17448301
Source Type: Journal
DOI: 10.2217/fon.10.59 Document Type: Review |
|
Times cited : (9)
|
|
References (69)
|
